2,4,5-Trifluorophenylacetic acid CAS NO.209995-38-0

Anqing World Chemical Co.,Ltd.Mainly responsible for the development of domestic and international business.In 2015,Haikang established the second branch,called Anqing Xuanyu Medical&Technology Co., Ltd, it is an R&D company that selects reliable technology and cooperative research partner for our corporation.

Haikang is committed to R&D,manufacture and sales of chemical raw materials API and intermediates.Meanwhile,we also provide services like product customization,process improvement,achievement transfer, etc. Through years effort,Haikang has made remarkable achievements in the R&D and production of anti-virus,antidiabetic,antineoplastic,beauty and whitening resist oxidation series API and intermediates.The main products are Ganciclovir, Sitagliptin, Vildagliptin, Silodosin and Imatinib API and Intermediates.

To deal with increasingly competition,Haikang adheres to “Customer is First,Technology is Leading,Quality is Life,Honesty for Developing”,and optimizes actively the products and better service to customers.

Sitagliptinphosphate (Trade name Januvia, code MK-0431) is abbreviated as Sitagliptin, produced by Merck, and was approved by the US Food and Drug Administration (FDA) in October 2006 for treatment Type 2 Sugar Chemicalbook Urinary Disease. Sitagliptin phosphate is very effective in treating type 2 diabetes. As a new type of anti-diabetic drug, sitagliptin phosphate is blood sugar-dependent, has a moderate hypoglycemic effect, increases insulin secretion without hypoglycemia, effectively reduces hunger and other advantages, and has no nausea, vomiting, edema and increase Side effects such as body weight.

Sitagliptin has the effect of lowering blood sugar and has good safety. It basically has no side effects such as weight gain, nausea, and vomiting, and there are few cases of hypoglycemia, which is well tolerated by patients. A 24-week randomized, double-blind, placebo-controlled study involving 741 patients (HbA1c is 8.0%) evaluated the safety and tolerability of sitagliptin. Participants were divided into 3 groups: sitagliptin 100mg group and 200mg group, once a day; placebo group. Results Maiming, compared with the placebo group, the other two groups had no obvious side effects, and its safety and tolerability were good. There was basically no hypoglycemia, no nausea, vomiting, etc., and the patient’s weight did not increase. The probability of occurrence is >2%. However, there are some special adverse reactions that are significantly different from the placebo group, such as constipation, rhinitis, pharyngitis, sore throat, urinary tract infection, myalgia, arthralgia, high blood pressure, dizziness and other symptoms, but the degree of reaction is mild. To moderate, it is also self-limiting. The results of laboratory tests were basically normal, except that the content of alkaline phosphatase was slightly decreased, and the absolute counts of white blood cells and neutrophils were slightly increased, but it was not accompanied by any clinical symptoms, which may not have a significant clinical effect. significance.